Addus HomeCare Corporation (ADUS) Stock Price & How to Invest

Addus HomeCare Corporation provides in-home care to elderly, chronically ill, and disabled people through three segments: personal care (help with bathing, dressing, meals, and daily activities), hospice (end-of-life care), and home health (skilled nursing and therapy). Personal care is by far the largest piece at roughly 77% of revenue and is funded predominantly by state Medicaid programs, while hospice and home health are largely Medicare-funded. The company operates across many states with heavy concentration in markets like Illinois, New Mexico, and Texas, and has grown for years through a steady stream of acquisitions, most recently a large personal care deal that lifted 2025 revenue sharply. In September 2026 it agreed to acquire AccentCare's personal care division in Illinois and Texas for $275 million, a deal valued at roughly 10.8x current EBITDA before synergies and expected to close in the first half of 2027.

The investment picture is one of defensive, demographically supported growth rather than rapid expansion. Revenue and earnings compound at mid-to-high single digits organically, supplemented by M&A, and margins are thin but stable because the business is labor-intensive and reimbursement-rate driven. Second-quarter 2026 revenue was about $377.4 million, up roughly 8% year over year, and adjusted EPS of $1.73 edged past the $1.70 consensus; trailing revenue is about $1.48 billion and trailing net income about $105 million. The shares closed at $116.97 on October 16, 2026, up about 10% in 2026 but flat over a year. The stock tends to react most to Medicaid and Medicare rate decisions, caregiver labor availability, and acquisition cadence, so the core question for an owner is confidence in the durability of government-funded home care as the population ages.

The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. Proposed Medicaid or Medicare funding changes at the federal level are a recurring overhang, and the pending AccentCare deal adds to Addus's exposure to Illinois and Texas Medicaid programs. The business is labor-intensive, so caregiver wage inflation, turnover, and staffing shortages can squeeze already thin margins (a net margin near 7%). Integration risk, closing risk on the AccentCare purchase, and the possible use of debt to fund it add execution and balance-sheet sensitivity. Finally, regulatory and compliance exposure across many states and government payers means audits, documentation requirements, and policy shifts are an ongoing part of the model.

13 analysts publish price targets on ADUS, averaging $134.08 against a $115.98 price as of October 2026, or +15.6%. The published targets run from $96.00 to $155.00, a moderate spread, and the ratings split 11 buy, 2 hold, 1 sell. Over the last six months there have been 2 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full ADUS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Addus HomeCare Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Aging demographics and shift to home. The 65-plus population is growing quickly and both payers and families increasingly prefer care delivered at home over institutional settings because it is cheaper and often preferred. The most optimistic published target, $155.00, assumes this works close to its best case.

The case against. The largest risk is reimbursement concentration: personal care depends heavily on state Medicaid budgets and hospice and home health on Medicare, so rate cuts, budget shortfalls, or eligibility changes in key states can pressure revenue and margins directly. The most pessimistic target, $96.00, is roughly what ADUS is worth if this bites instead.

Read the full bull and bear case on ADUS, including what would have to change to break either one. Walnut is not an investment adviser.

No. Addus HomeCare Corporation (ADUS) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Addus HomeCare Corporation's investor relations page or your broker.

• Revenue (TTM): ~$1.48B
• FY2025 revenue: ~$1.42B (up ~23%)
• Q2 2026 revenue: ~$377.4M (up ~8%)
• Q2 2026 adjusted EPS: ~$1.73 (vs ~$1.70 estimate)
• Net income (TTM): ~$105M (~7% margin)
• P/E (trailing / forward): ~20.5x / ~15.6x
• Market cap: ~$2.2B

Addus trades near 20x trailing GAAP earnings and about 15.6x forward estimates, a valuation for a steady, profitable services operator rather than a high-growth name. Analysts expect 2026 revenue of about $1.52 billion and adjusted EPS of about $7.05. The third-quarter report on November 3, 2026 (consensus EPS about $1.79 on $388.7 million of revenue) is the next checkpoint, and the AccentCare deal is expected to add to growth in 2027 and 2028 once it closes.

Other names that sit close to ADUS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get ADUS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ADUS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where ADUS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

ADUS is a durable, acquisitive home-care operator whose fortunes track demographics and state/federal reimbursement policy more than product cycles. 2026 has followed the usual pattern, with revenue up about 8% in the second quarter, earnings beating estimates, and a new $275 million personal care acquisition in Illinois and Texas that is expected to close in the first half of 2027.

Whether ADUS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ADUS a buy or a sell?, and where the stock could go from here in the ADUS stock forecast.

For income investors, whether ADUS pays a dividend and how the payout looks is covered in does ADUS pay a dividend? And to weigh ADUS against a peer, read the full side-by-side comparisons: ADUS vs EHC and ADUS vs UNH.